Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728160 | 1.00 | EPHX1 (0.33) | EPHX1NCF1TP53KDM4EGMNN | |
| SCHEMBL19300340 | 1.00 | EPHX1 (0.33) | EPHX1NCF1TP53KDM4EGMNN | |
| SCHEMBL19728161 | 1.00 | EPHX1 (0.33) | EPHX1NCF1TP53KDM4EGMNN | |
| SCHEMBL10177714 | 1.00 | EPHX1 (0.33) | EPHX1NCF1TP53KDM4EGMNN | |
| SCHEMBL12014105 | 0.86 | NCF1 (0.34) | NCF1LMNA | |
| SCHEMBL7492568 | 0.85 | EPHX1 (0.32) | EPHX1NCF1TP53 | |
| SCHEMBL21510159 | 0.85 | — | — | |
| SCHEMBL25868537 | 0.83 | TP53 (0.38) | EPHX1NCF1TP53KDM4EGMNN | |
| SCHEMBL16191176 | 0.82 | SHBG (0.31) | — | |
| SCHEMBL16192875 | 0.82 | SHBG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | Epizyme, Inc. (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | Epizyme, Inc. (US) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | EPHX1 4037/4885NCF1 2077/4885TP53 62/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | EPHX1 2855/4885NCF1 2060/4885TP53 666/4885 |
| US-20170247326-A1 | Substituted Pyrrolidine Carboxamide Compounds | SMYD3, SMYD2, SMURF2 | EPHX1 4167/4885NCF1 1995/4885TP53 109/4885 |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | EPHX1 3678/4885NCF1 3433/4885TP53 88/4885 |
| US-20170253601-A1 | Substituted Pyrrolidine Compounds | SMYD2, SMYD3, SNRPD2 | EPHX1 3908/4885NCF1 2287/4885TP53 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.